Sep 13, 2022 / 03:10PM GMT
Tejas Rajeev Savant - Morgan Stanley, Research Division - Equity Analyst
Hey, everyone. Thanks for joining us. My name is Tejas Savant, and I'm the life science tools and diagnostics analyst at Morgan Stanley. It's my pleasure to host IQVIA this morning. And representing the company, we have Ron Bruehlman, CFO. So thanks, Ron, for doing this.
Ronald E. Bruehlman - IQVIA Holdings Inc. - Executive VP & CFO
You're very welcome.
Tejas Rajeev Savant - Morgan Stanley, Research Division - Equity Analyst
Before we get started, a quick disclaimer statement, please go to morganstanley.com/researchdisclosures. And if you have any questions, do reach out to your sales rep.
Questions and Answers:
Tejas Rajeev Savant - Morgan Stanley, Research Division - Equity AnalystSo perhaps, Ron, just to kick things off, can you just outline what you view as IQVIA's key accomplishments this year? And what are you most excited about as you look to 2023?
Ronald E. Bruehlman